多参数磁共振-经直肠超声融合靶向穿刺对比14针前列腺穿刺活检的增量诊断价值:一项前瞻性对照研究
单中心、经IRB批准的前瞻性盲法研究纳入100例临床实验室怀疑前列腺癌且Likert评分≥3分的连续男性,先行14针经直肠超声引导随机穿刺(操作者对mpMRI数据盲),再行mpMRI-TRUS融合靶向穿刺;总体癌症检出率从随机穿刺的56%升至联合靶向穿刺的62%,临床显著病变(Gleason≥7)检出率提高10%。
要点
- mpMRI-TRUS融合靶向穿刺使总体前列腺癌检出率从随机穿刺的56%升至联合靶向穿刺的62%。
- 融合靶向穿刺使临床显著病变(Gleason≥7)检出率提高10%。
- 5例随机穿刺阴性者经融合靶向穿刺诊断为临床显著肿瘤,5例随机穿刺为临床不显著而融合靶向穿刺为显著肿瘤(p=0.0010)。
核心结论
- 与常规随机穿刺相比,mpMRI-TRUS融合靶向穿刺具有增量诊断价值,能更好地检出临床显著前列腺癌。
研究设计与样本
- 单中心、经机构审查委员会(IRB)批准的前瞻性盲法对照研究,纳入100例连续男性;研究对象为临床实验室怀疑前列腺癌且Likert评分≥3分的患者,排除既往确诊前列腺癌者;所有患者先行14针TRUS引导随机穿刺(操作者对mpMRI数据盲),随后行mpMRI-TRUS融合靶向穿刺。
诊断标准与关键数值
- 总体癌症检出率:随机穿刺56%,联合靶向穿刺62%;临床显著病变(Gleason≥7)检出率:融合靶向穿刺技术提高10%。
临床应用与阅片要点
- 联合使用mpMRI-TRUS融合靶向穿刺与14针随机穿刺可提高临床显著前列腺癌的检出;原文要点指出无证据支持仅获取mpMRI-TRUS融合穿刺针芯。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare the incremental diagnostic value of targeted biopsy using real-time multiparametric magnetic resonance imaging and transrectal ultrasound (mpMRI-TRUS) fusion to conventional 14-cores biopsy.
PATIENTS AND METHODS: Uni-institutional, institutional review board (IRB) approved prospective blinded study comparing TRUS-guided random and targeted biopsy using mpMRI-TRUS fusion, in 100 consecutive men. We included men with clinical-laboratorial suspicious for prostate cancer and Likert score ≥ 3 mp-MRI. Patients previously diagnosed with prostate cancer were excluded. All patients were submitted to 14-cores TRUS-guided biopsy (mpMRI data operator-blinded), followed by targeted biopsy using mpMRI-TRUS fusion.
RESULTS: There was an overall increase in cancer detection rate, from 56% with random technique to 62% combining targeted biopsy using mpMRI-TRUS fusion; incremental diagnosis was even more relevant for clinically significant lesions (Gleason ≥ 7), diagnosing 10% more clinically significant lesions with fusion biopsy technique. Diagnosis upgrade occurred in 5 patients that would have negative results in random biopsies and had clinically significant tumours with the combined technique, and in 5 patients who had the diagnosis of significant tumours after fusion biopsy and clinically insignificant tumours in random biopsies(p=0.0010).
CONCLUSIONS: Targeted biopsy using mpMRI-TRUS fusion has incremental diagnostic value in comparison to conventional random biopsy, better detecting clinically significant prostate cancers.
KEY POINTS: • mpMRI-TRUS targeted biopsy increases overall cancer detection rate, but not statistically significant. • mpMRI-TRUS targeted biopsy actually improves the diagnosis of clinically significant PCa. • There was no evidence to acquire the mpMRI-TRUS fusion cores alone.
引用
- Mariotti GC, Falsarella PM, Garcia RG, et al. Incremental diagnostic value of targeted biopsy using mpMRI-TRUS fusion versus 14-fragments prostatic biopsy: a prospective controlled study. Eur Radiol. 2017. PMID: 28687911. doi:10.1007/s00330-017-4939-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。